A Novel Genomic Variant Algorithm for Identifying the Pathological Mechanism of Rare Genetic Diseases in Order to Target Personalized Therapies
ISEF · 2024 Translational Medical Science Fourth Award
Overview
I propose a method that enables the development of treatments for the 350 million people worldwide suffering from 7,000 rare genetic diseases. Genomic therapies for rare genetic diseases are possible if the underlying genetic variations are known due to the invention of gene editing technology such as CRISPR. However, these therapies are prohibitively expensive and are typically only employed and justified in cases of diseases with large cohorts, such as sickle cell anemia and cystic fibrosis. Ongoing research is being done to reduce these expenses in the hope that they will become economically viable in the near future. In order to enable personalized patient care, it is essential to identify genetic variants of clinical significance. Without the identification, targeted therapies may not be developed. In the case of many rare genetic diseases, very few people have the disease, leading to small cohorts. It is presently difficult and expensive to identify the underlying genetic variants of clinical significance because whole genome sequencing analysis requires large cohorts on the order of 100 people. I developed a novel genomic variant algorithm to identify the variants of clinical significance for cohorts as small as two by augmenting whole genomic sequencing with clinical presentation of the disease, mode of inheritance, generational data, and organ-specific gene expression. I demonstrate the method to two members of a family suffering from Children’s Interstitial Lung Disease (ChILD), a rare genetic disorder affecting 1 in 100,000 individuals in the United States. Using this method, I identified a variant of clinical significance for ChILD in the CLEC4M gene. The method is extensible to all rare genetic diseases.
Awards (1)
- Fourth Award of $500 $500
Competition history
- ISEF 2024
Resources
Related projects
ISEF · 2017
Developing Novel Gene Candidates (MEF2A, LTA, LGALS2, ALOX5AP, and PDE4D), through an Adaptive Genetic Algorithm, Support Vector Cluster, and Dynamic Bayesian Networks, to Analyze in a Learning Classifier System for a Highly Propitious CRISPR Therapy for Ischemic Heart Disease
ISEF · 2020
Identifying Novel Cis-Regulatory Elements in the Viral Genome of Adeno-Associated Virus (AAV) for Increased Genetic Modification Efficiency
CWSF · 2026
Utilizing gene-editing and stem cell therapy to create a novel treatment plan for Tay-Sachs disease
CYSF · 2026
Evaluating Gene Therapy as a Treatment for ABCA3-Related Congenital Surfactant Deficiency
ISEF · 2022
Identification of X-Linked Candidate Disease Genes Through Trio Family Analysis of Family Pedigree
ISEF · 2021
Refinement of SNP Mutations of Atopic Dermatitis Related Filaggrin Through Existing R Packages
ISEF · 2021
Development of a Protocol for Simultaneously Sequencing Multiple Inherited Retinal Diseases’ Founder Mutations
ISEF · 2022
The Use of Prime Editing To Induce and Correct the CFTR-F508del Mutation in Induced Pluripotent Stem Cells
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: Regeneron International Science and Engineering Fair